Screener
Monopar Therapeutics MNPR Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | March 31, 2026 | December 31, 2025* |
|---|---|---|
| Other current assets | 250,903 | 63,745 |
| Total current assets | 137,743,843 | 140,462,788 |
| Operating lease right-of-use asset | 239,882 | 254,921 |
| Total assets | $137,983,725 | $140,717,709 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable, accrued expenses and other current liabilities | $2,457,748 | $2,735,236 |
| Total current liabilities | 2,457,748 | 2,735,236 |
Document
FAQ
- What is Monopar Therapeutics's total assets?
- Monopar Therapeutics (MNPR) reported total assets of $137.98M in Q1 2026.
- How has Monopar Therapeutics's total assets changed year-over-year?
- Monopar Therapeutics's total assets increased by 150.5% year-over-year, from $55.09M to $137.98M.
- What is the long-term trend for Monopar Therapeutics's total assets?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total assets has grown at a 52.8% compound annual growth rate (CAGR), from $16.87M to $140.72M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Monopar Therapeutics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude